Antithrombotic Clinical Trial
— APPOfficial title:
Effectiveness of the Application on Individualized Antithrombotic Therapy in Chinese Patients With Coronary Artery Disease
Develop an exemplary anti-thrombotic therapy network data platform and a intelligent terminal application(APP), establish an new pattern used in long-time anti-thrombotic management based on dynamic risk evaluation, and promoted and verified by 10 thousands large sample's cohort study.
Status | Recruiting |
Enrollment | 10000 |
Est. completion date | December 20, 2020 |
Est. primary completion date | December 30, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - age=18 years; - clinical confirmed coronary heart disease. Including definite history of myocardial infarction, stable angina with exercise electrocardiography test(treadmill exercise) positive, unstable angina with electrocardiogram(ECG) ischemic changes or troponin positive, coronary angiography(CAG) hints at least one coronary artery stenoses over 50%, post-operative of percutaneous coronary intervention(PCI) or coronary artery bypass grafting(CABG); - Be receiving anti-thrombotic therapy; - Be voluntary to participate in the study., and sign informed consent form. Exclusion Criteria: - inability to obtain consent from participants; - unable to record the medical data through terminal applications(APP) |
Country | Name | City | State |
---|---|---|---|
China | Guangdong General Hospital | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Guangdong General Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | adverse clinical events | net adverse clinical events during 2 years follow-up, including death, myocardial infarction, stroke, ischemia induced target vessel revascularization, BARC type 2-5 bleeding | 2 years | |
Primary | BRAC 2-5 type bleeding | defined as bleeding event graded 2 to 5 of Standardized bleeding definitions from the Bleeding Academic Research Consortium(BRAC) | 2 years | |
Secondary | heart and cerebral vessels ischemia | adeverse events of vascular death, myocardial infarction and stroke | 2 years | |
Secondary | readmission | incidence of readmission during 2-year follow-up | 2 years | |
Secondary | angina recurrence | incidence of angina recurrence during 2-year follow-up | 2 years | |
Secondary | treatment discontinuation | incidence of treatment discontinuation during 2-year follow-up | 2 years | |
Secondary | drug-related events | incidence of drug-related adverse reaction during 2-year follow-up | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03000673 -
A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With Hemodialysis
|
Phase 1/Phase 2 |